Is Anavex Life Sciences Stock a Buy Now?

Anavex Life Sciences (NASDAQ: AVXL) is a small-cap stock with big ambitions. It has a potential Alzheimer's treatment that fared well in recent trials and could be a game-changer for the business. But the company remains unprofitable, and the stock is heavily shorted and volatile.

Is Anavex Life Sciences too risky a buy, or is this an investment you might consider adding to your portfolio today?

The consensus analyst price target for Anavex is $41.80, which represents an upside of more than 300% from where the stock is right now. While some analysts are less bullish, analysts by and large expect to see Anavex rise in value in the near term.

Continue reading


Source Fool.com